Regenxbio Inc (RGNX)
14.92
-0.04
(-0.27%)
USD |
NASDAQ |
May 24, 16:00
14.93
+0.01
(+0.07%)
After-Hours: 20:00
Regenxbio Research and Development Expense (TTM): 228.59M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 228.59M |
| December 31, 2023 | 232.27M |
| September 30, 2023 | 239.09M |
| June 30, 2023 | 244.22M |
| March 31, 2023 | 245.34M |
| December 31, 2022 | 242.45M |
| September 30, 2022 | 227.93M |
| June 30, 2022 | 212.47M |
| March 31, 2022 | 197.34M |
| December 31, 2021 | 181.44M |
| September 30, 2021 | 180.64M |
| June 30, 2021 | 176.75M |
| March 31, 2021 | 168.98M |
| December 31, 2020 | 166.29M |
| September 30, 2020 | 152.92M |
| June 30, 2020 | 144.64M |
| March 31, 2020 | 136.02M |
| December 31, 2019 | 124.18M |
| Date | Value |
|---|---|
| September 30, 2019 | 114.71M |
| June 30, 2019 | 97.52M |
| March 31, 2019 | 89.53M |
| December 31, 2018 | 83.87M |
| September 30, 2018 | 73.71M |
| June 30, 2018 | 67.72M |
| March 31, 2018 | 60.16M |
| December 31, 2017 | 57.22M |
| September 30, 2017 | 59.11M |
| June 30, 2017 | 59.16M |
| March 31, 2017 | 55.92M |
| December 31, 2016 | 45.48M |
| September 30, 2016 | 34.23M |
| June 30, 2016 | 27.34M |
| March 31, 2016 | 20.67M |
| December 31, 2015 | 17.28M |
| September 30, 2015 | 14.56M |
| June 30, 2015 | 9.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
97.52M
Minimum
Jun 2019
245.34M
Maximum
Mar 2023
185.69M
Average
181.04M
Median
Research and Development Expense (TTM) Benchmarks
| Sarepta Therapeutics Inc | 832.10M |
| AbbVie Inc | 7.322B |
| PTC Therapeutics Inc | 587.57M |
| BridgeBio Pharma Inc | 503.82M |
| Edgewise Therapeutics Inc | 98.72M |